Hydrogen sulfide promotes autophagy of hepatocellular carcinoma cells through the PI3K/Akt/mTOR signaling pathway

Shanshan S Wang,1,2,6 Yuhan H Chen,1,6 Ning Chen,1,6 Lijun J Wang,4 Dexi X Chen,5 Honglei L Weng,5 Steven Dooley5 and Huiguo G Ding1

Hydrogen sulfide (H2S), in its gaseous form, plays an important role in tumor carcinogenesis. This study investigated the effects of H2S on the cell biological functions of hepatocellular carcinoma (HCC). HCC cell lines, HepG2 and HLE, were treated with NaHS, a donor of H2S, and rapamycin, a classic autophagy inducer, for different lengths of time. Western blotting, immunofluorescence, transmission electron microscopy (TEM), scratch assay, CCK-8 and flow cytometric analysis were carried out to examine the effects of H2S on HCC autophagy, cell behavior and PI3K/Akt/mTOR signaling. Treatment with NaHS upregulated expression of LC3-II and Atg5, two autophagy-related proteins, in HepG2 and HLE cells. TEM revealed increased numbers of intracellular double-membrane vesicles in those cells treated with NaHS. Like rapamycin, NaHS also significantly inhibited expression of p-PI3K, p-Akt and mTOR proteins in HCC cells. Interestingly, the expression of LC3-II was further increased when the cells were treated with NaHS together with rapamycin. In addition, NaHS inhibited HCC cell migration, proliferation and cell division. These findings show that H2S can induce HCC cell apoptosis. The biological function of the gasotransmitter H2S in HCC cells was enhanced by the addition of rapamycin. Hydrogen sulfide influences multiple biological functions of HCC cells through inhibiting the PI3K/Akt/mTOR signaling pathway. Cell Death and Disease (2017) 8, e2688; doi:10.1038/cddis.2017.18; published online 23 March 2017

Hydrogen sulfide (H2S) is the most recently discovered gas that is synthesized in mammalian cells. Like nitric oxide (NO) and carbon monoxide (CO), which contribute to tissue damage and inflammation,1,2 H2S exerts multiple physiological and pathological effects on cell growth, differentiation and proliferation. This gas has been reported to influence cardiovascular remodeling, change vascular active substances, damage the gastric mucosal and have important biphasic effects in cancer.3,4

The liver is one of the most important organs that produce and clear H2S.5 Endogenous H2S participates in the pathogenesis of many liver diseases, affecting processes such as deregulation of hepatic lipid6 and glucose metabolism,7 oxidative stress,8 mitochondrial bioenergetics,9 fibrosis,10 cirrhosis,11 hepatoprotection and hepatotoxicity.12 In addition, endogenous or exogenous H2S may play an important role in the occurrence and development of liver tumors. In the liver, synthesis and clearance of H2S are mainly managed by hepatic stellate cells (HSC), the major cell source of extracellular matrix in liver fibrosis and HCC.13,14

Autophagy is the natural, destructive cellular mechanism that degrades damaged proteins and cytoplasm components in lysosomes and thus maintains cellular homeostasis and supplies substrates for energy generation. It is a critical pathway for homeostasis, development and other pathophysiological processes.15,16 Autophagy plays an important role in the healthy and diseased liver.16,17 Some molecular mechanisms of autophagy have been investigated in liver disease, especially in HCC. For example, the PI3K/Akt/mTOR signaling pathway is reported to play an important role in cell autophagy.18 Previous experiments indicated that autophagy is a double-edged sword, acting both to promote and inhibit tumor growth, and development in different experimental settings.

This study investigated the role and underlying mechanisms of H2S on autophagy of HCC cells.

Results

HepG2 cells were treated with 10−4 M and 10−3 M NaHS for 24 h, then western blotting and immunofluorescence staining show that the more significantly effective NaHS dosage was 10−3 M (see the Supplementary Figure 1). To examine the effect of H2S on HCC cells, HepG2 and HLE cells were treated with NaHS at a final concentration of 10−3 M for 24 h, then western blotting, immunofluorescence staining and TEM assays were used to detect markers of autophagy and morphological alterations in these cells. Western blotting demonstrated that H2S treatment significantly upregulated...
protein expression of LC3-I, LC3-II and autophagy-related protein Atg5, and reduced p62 expression in both the cell lines (Figures 1a and b). Immunofluorescence analyses further confirmed that H2S drastically increased the expression of LC3 in both HepG2 and HLE cells (Figure 1c). Compared with untreated cells, the percentage of LC3-positive cells increased in HepG2 (64.7 ± 3.15% versus 8.77 ± 0.89%) and HLE (47.87 ± 6.93% versus 7.0 ± 0.52%) cells after NaHS treatment (Figure 1d, *P < 0.05). Consistent with western blot findings, immunofluorescence staining also demonstrated reduced p62 in 24 h H2S-treated cells (Figure 1e). Furthermore, TEM showed increased numbers of mitochondria encircled by double-membrane structures resembling autophagosomes in H2S-treated cells than in control cells(Figure 1f).

H2S inhibits cell migration and proliferation, but induces apoptosis. The effects of H2S on HCC cell migration were evaluated by starch test. The results showed that migration of both HepG2 (Figure 2a) and HLE (Figure 2e) cells was slightly inhibited following NaHS treatment for 12 h compared with the control group. The CCK-8 assay showed that proliferation of both HepG2 and HLE cells was also inhibited after 24 h H2S treatment (Figures 2b and f). Immunofluorescence staining forM30 protein, an apoptosis-related protein, showed that H2S...
induced early apoptosis in both HepG2 and HLE cells (Figures 2c and g). Flow cytometric analyses further found that when cells were exposed to H$_2$S, there were fewer cells in S phase (HepG2: 24.09% ± 0.37; HLE: 24.41% ± 0.19) compared to those without treatment (HepG2: 30.49% ± 0.15; HLE: 29.97% ± 0.21) (Figures 2d and h).

**H$_2$S induces cell autophagy by inhibiting the PI3K/AKT/mTOR signaling pathway.** Next, western blotting analyses showed that H$_2$S treatment significantly decreased expression of phosphorylated-PI3K (p-PI3K), phosphorylated-Akt (p-Akt) and mTOR (Figures 3a and b) in HepG2 and HLE cells. Given that rapamycin induces cell autophagy by inhibiting mTOR expression, we speculate that like rapamycin, H$_2$S induces HCC cell autophagy by inhibiting the PI3K/AKT/mTOR signaling pathway. As expected, the expression of LC3-II was increased by treatment with either H$_2$S or rapamycin alone in both HepG2 and HLE cells. Combined administration of H$_2$S together with rapamycin further significantly increased the expression of LC3-II (Figures 3c and d), probably because both of them influence the PI3K/AKT/mTOR signaling pathway. Consistent with findings from western blotting, TEM further

---

**Figure 2** Hydrogen sulfide inhibits cell migration, proliferation and cell cycle progression, but accelerates apoptosis. Scratch assay was used to evaluate cell migration. HepG2 (a) and HLE (e) cells were treated with NaHS for 48 h then viewed, and images were captured under a light microscope at 0, 12, 24, 36 and 48 h separately (Scale bar: 20 μm). CCK-8 assay was used to verify HepG2 (b) and HLE (f) cell proliferation. Immunofluorescence was used to evaluate M30 immunoreactivity in HepG2 (c) and HLE (g) cells. M30 staining was red and nuclei were blue (Scale bar: 100 μm). Flow cytometry was used to analyze the cell cycle of HepG2 (d) and HLE (h) cells after NaHS treatment for 24 h. The data represents the mean ± S.D. of three samples. All the data are representative of an experiment that was repeated at least three times.
demonstrated that the quantity of double-membrane autophagosomes significantly increased in HepG2 and HLE cells treated with NaHS together with rapamycin when compared to those treated with either compound alone (Figure 3e).

**H₂S and rapamycin additively inhibit the migration, proliferation and cell cycle of HCC cells.** To further test the additive effects of H₂S and rapamycin on cell migration, proliferation and division, the scratch assay, CCK-8 assay and flow cytometric analyses were carried out. Compared to the individual treatments, combined H₂S and rapamycin administration further reduced cell migration (Figures 4a and d). CCK-8 assay showed that proliferation of both HepG2 and HLE cells was further inhibited by combined H₂S and rapamycin treatment (70 and 75%) compared to treatment with H₂S or rapamycin separately (Figures 4b and e). Both HepG2 and HLE cells underwent obvious cell cycle arrest with combined H₂S and rapamycin treatment (Figures 4c and f).

**Discussion**

The data gathered in this study suggest that treatment of HepG2 and HLE cells with NaHS promoted cell autophagy...
Rapamycin and H$_2$S additively inhibit the migration, proliferation and cell cycle of liver cancer cells. Scratch assay was performed to detect HepG2 (a) and HLE (d) cell migration under different treatments (Scale bar: 200 μm). HepG2 (b) and HLE (e) cell proliferation was calculated by CCK-8 assay. The data represents the mean ± S.D. of three samples. HepG2 (c) and HLE (f) cells were incubated under different conditions for 24 h then analyzed by flow cytometry to investigate the cell cycle. The data are representative of an experiment that was repeated at least three times.
and apoptosis, and also inhibited cell migration, proliferation and cell cycle progression. Further experimental results suggested that the effects of NaHS may be mediated by the PI3K-Akt signaling pathway, and this was confirmed by the additional effect of rapamycin.

There are two forms of H₂S in the body: most H₂S exists as sodium hydrosulfide (NaHS) with a minor amount in the form of the gas. In this study, we used exogenous NaHS as a donor of H₂S gas. There has been some previous research carried out into the relationship of H₂S and autophagy. Gotor et al. reported that in plant cells, sulfide plays a biological role through negative regulation of autophagy, which is unrelated to nutrient deficiency. Another study produced contradictory results, showing that when the H₂S level increased in chickens, autophagy also correspondingly increased. In this study, our first result demonstrated that autophagy of HCC cells is enhanced following treatment with 10⁻³ M NaHS for 24 h.

The biological function of H₂S also has generated a great deal of controversy, with some studies indicating that H₂S promoted cell proliferation, while others showed that H₂S induced cell apoptosis. One study found that cell proliferation was stimulated by treatment with low concentrations of H₂S, but inhibited at high concentrations. Meanwhile, research in colon cells verified that H₂S could inhibit cell proliferation and arrest the cell cycle, findings which are similar to our results.

In our second result, we demonstrate that H₂S treatment of HepG2 and HLE cells can induce apoptosis, inhibit the cell cycle and proliferation, and block cell migration.

One recent study in esophageal cells verified that exogenous H₂S promoted proliferation, inhibited apoptosis and increased migration through the HSP90 pathway. Meanwhile, other reports verified that the effects of H₂S involve the PI3K/Akt/mTOR signaling pathway. There are several signaling pathways involved in cell autophagy, such as the PI3K/Akt/mTOR, Bcl2/becin1, MAPK/Erk1/2, and AMPK signaling pathways. But the PI3K/Akt/mTOR signaling pathway is becoming increasingly difficult to ignore in the investigation into the mechanism of cell autophagy. Rapamycin, which acts through specifically inhibiting mTOR in the PI3K/Akt pathway, is recognized to be a drug which promotes autophagy. Both NaHS and rapamycin reduce the expression of mTOR, so when the two are combined, any increase in autophagy should be more significant. As we envisaged, when rapamycin was added together with H₂S treatment, the enhancement of autophagy was more significant. These results indicate that the induction of autophagy by H₂S may be mediated by inhibition of the PI3K/Akt/mTOR signaling pathway. Further functional experimental results confirmed our hypothesis.

The emerging role of H₂S in liver cancer may open a new therapeutic approach. The toxic effects of H₂S are well recognized, and recently many studies have added to the evidence that H₂S may act as a mediator of some aspects of liver function. However, the exact function of H₂S remains controversial, and its precise mechanism remains to be elucidated. In conclusion, our results demonstrate that H₂S is involved in liver cancer and that its effects are mediated through the PI3K/Akt/mTOR signaling pathway.

Materials and Methods

Cells. HepG2 and HLE cells, two HCC cell lines, were obtained from the Beijing Institute of Hepatology. Cells were cultured in DMEM supplemented with 10% fetal calf serum (FCS) at 37°C in a 5% CO₂ incubator.

Western blotting. Western blotting was performed to analyze the expression of autophagy-associated proteins in HepG2 and HLE cells. Briefly, cells were collected and lysed in ice-cold RIPA lysis buffer (1× Tris-buffered saline, 1% Nonidet P-40, 0.5% sodium deoxycholate, and 0.1% sodium dodecyl sulfate (SDS)), then 40 μg of cell lysate from each sample was separated by 10% SDS-polyacrylamide gel electrophoresis (PAGE). Electrophoretic transfer of proteins from gels onto nitrocellulose membranes was carried out in a transblotting chamber. Membranes were blocked by immersing in 5% nonfat milk (w/v) in phosphate-buffered saline (PBS) for 1 h to inhibit nonspecific binding before being incubated with primary antibodies at room temperature for 2 h. After rinsing with PBS/0.1% Tween-20, membranes were incubated with horseradish peroxidase-conjugated secondary antibodies (Zhongshan Boil Tech Co, Beijing, China). Immunocomplexes were visualized by incubation using an enhanced chemiluminescence system (Thermo Fisher Scientific, OL19120A, MA, USA) and were exposed on X-ray film. Western blotting was repeated at least three times for each experiment.

Transient transfection of a GFP-LC3-expressing construct. A GFP-LC3-expressing construct was provided by the Beijing Institute of Hepatology. The GFP-LC3 plasmid was transfected into the cells using the FuGene Transfection Method according to the protocol provided by Roche Diagnostics. The number of GFP-LC3-positive cells was counted manually in five randomly-selected fields under a fluorescence microscope (LEICA CTR5000, Leica Microsystems Ltd, Wetzlar, Germany). Cell nuclei were visualized by staining with 4,6-diamidino-2-phenylindole (DAPI).

Immunofluorescence. HepG2 and HLE cells were treated with NaHS (10⁻³ M), a donor of H₂S, for 24 h. Then cells were fixed in ice-cold 4% paraformaldehyde/PBS for 15 min and soaked in 0.5% Triton X-100/ PBS for 20 min. After washing three times with PBS and blocking with 3% bovine serum albumin (BSA) in PBS for 30 min, the cells were incubated with the primary antibodies (anti-P62 and anti-M30) overnight at 4°C. The next day, the cells were washed in PBS then incubated with the appropriate secondary antibody conjugated with fluorescent isothiocyanate (FITC) or rhodamine (TRITC) for 1 h at 37°C. Cell nuclei were counterstained with DAPI. Cells were viewed under a fluorescence microscope (Nikon Eclipse 80i; Nikon, Tokyo, Japan). Quantitative analysis of apoptosis was performed by counting more than 500 cells in each sample.

Transmission electron microscopy (TEM). Cells were fixed in 2.5% glutaraldehyde and 0.1 M cacodylate buffer (pH 7.4) for 2 h following trypsinization and rinsed twice with precooled PBS. After washing with buffer solution, cells were post-fixed in 1% osmium tetroxide (OsO₄) and 0.1 M cacodylate buffer (pH 7.4). Then, the fixed cells were washed with buffer solution, dehydrated through different concentrations of ethanol, and embedded in epoxy resin. The ultrastructures of cells undergoing autophagy were observed and imaged under TEM (JEM-1200, Tokyo, Japan).

Scratch test. Suspensions of HepG2 and HLE cells were pipetted into 6-well microplates at 5 × 10⁵ cells per well. After allowing them to completely attach, the cells were subjected to different treatments as: control, 10⁻³ M NaHS, 10⁻³ M NaHS+10⁻⁵ M rapamycin and 10⁻³ M NaHS+10⁻⁵ M rapamycin. Then, the cells were viewed under a light microscope at 0, 12, 24, 36 and 48 h following treatment.

CCK-8. The Cell Counting Kit (CCK)-8 was used to assess the effect of NaHS and rapamycin on cell proliferation according to the standard protocol from Dojindo Laboratories (Kumamoto, Japan). Briefly, 5 × 10³ HepG2 or HLE cells were pipetted into wells of a 96-well microplate and subjected to various treatments (NaHS and rapamycin) before analysis by the CCK-8 assay. The absorbances were measured at a wavelength of 450 nm on a Universal Microplate Reader (EL x800; Bio-Tek Instruments Inc., Winooski, VT, USA). Cell proliferation was calculated using the formula: Cell proliferation% = ([A570 or 450 sample – background]/(A570 or 450 control-background)) × 100%.

Cell cycle analyses. Before treatment, HepG2 and HLE cells were cultured in serum-free medium for 12 h to arrest the cell cycle, then the serum-free supernatant
was replaced by fresh medium containing 10% FCS. The cells were transferred into 12-well plates, treated with NaHS and rapamycin for 24 h, then stained with propidium iodide (PI) at a final concentration of 50 mg/l. DNA content was analyzed with a FACScan-420 flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA). The distribution of cells in different cell cycle stages was determined according to the DNA content.

Statistical analyses. Quantitative variables are expressed as mean ± S.D. on the basis of at least three separate experiments. Statistical significance was calculated by Student’s t-test (SPSS19.0, SPSS Inc. Chicago, IL, USA). \( P < 0.05 \) was considered significant.

Conflict of Interest
The authors declare no conflict of interest.

Acknowledgements. This study was supported by the national science Fund (81672275 and 81401970), Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding (ZYLC201610), Beijing Municipal Administration of Hospitals/Anticancer Plan (DFL20151602).

1. Fiorucci S, Distritto E, Cirino G, Wallace JL. The emerging roles of hydrogen sulfide in the gastrointestinal tract and liver. Gastroenterology 2006; 131: 259–271.
2. Wang R. Physiological implications of hydrogen sulfide: a whiff exploration that blossomed. Physiol Rev 2012; 92: 791–896.
3. Helmich MR, Szabó C. Hydrogen sulfide and cancer. Hand Exp Pharmacol 2015; 230: 233–241.
4. Wu D, Si W, Wang M, Lv S, Li Y. Hydrogen sulfide in cancer: friend or foe? Nitric Oxide 2015; 50: 38–45.
5. Whiteham M, Le Trionnaire S, Chopra M, Fox B, Whatmore J. Emerging role of hydrogen sulfide in health and disease: critical appraisal of biomarkers and pharmacological tools. Clin Sci 2011; 121: 459–488.
6. Meng TP, Anwar AB, Ng DS, Atan MSBM, Kumar SD, Moore PK. Effect of feeding a high fat diet on hydrogen sulfide (H2S) metabolism in the mouse. Nitric Oxide 2014; 41: 138–145.
7. Mari S, Cao W, Wu L, Wang R. Hydrogen sulfide and the liver. Nitric Oxide 2014; 41: 62–71.
8. Zheng JF, Zhao TT, Yuan Y, Hu N, Tang XQ. Hydrogen sulfide (H2S) attenuates acute nephrotoxicity through oxidative stress and inflammatory response via Nr2F-NF-κB pathways. Chem Biol Interact 2015; 242: 353–362.
9. Elrod JW, Calvert JW, Morrison J, Doeller JE, Kraus DW, Tao L et al. Hydrogen sulfide attenuates myocardial ischemia-reperfusion injury by preservation of mitochondrial function. Proc Natl Acad Sci USA 2007; 104: 15560–15565.
10. Zhang S, Pan C, Zhou F, Yuan Z, Wang H, Cui W et al. Hydrogen sulfide as a potential therapeutic target in fibrosis. Oxid Med Cell Longev 2015; 2015: 599407.
11. Tan G, Pan S, Li J, Dong X, Kang K,Zhao M et al. Hydrogen sulfide attenuates carbon tetrachloride-induced hepatotoxicity, liver cirrhosis and portal hypertension in rats. PLoS ONE 2011; 6: e25943.
12. Li L, Bhata M, Zhu YZ, Zhu YC, Ramnath RD, Wang JZ et al. Hydrogen sulfide is a novel mediator of lipopolysaccharide-induced inflammation in the mouse. PASEB J 2005; 19: 1195–1198.
13. Aman T, Bataille F, Spruus T, Muhlbauer M, Gabele E, Scholmerich J et al. Activated hepatic stellate cells promote tumorigenicity of hepatocellular carcinoma. Cancer Sci 2009; 100: 646–653.